Riskpilot← Back to searchSign inGet full accessNeurova AB
ABActiveOrg 5568415656Karlsgatan 4Medical specialists activities · NACE 8622Est. 20110 employees
Revenue 2024
SEK 0
EBITDA margin
—
-25% vs 2023
Equity ratio
83.1%
Financial strength
Net profit 2024
SEK 677K
-39% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -16K | -25% |
| Net profit | SEK 677K | -39% |
| Total assets | SEK 10,1M | -6% |
| Equity | SEK 8,4M | +9% |
| Employees | 0 | — |
Legal name
Neurova AB
Org number
5568415656
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
10 februari 2011
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolagets verksamhet är att erbjuda specialistläkartjänster inom psykiatriska områden såsom främst bedömningar, utredningar, konsultationer och utlåtanden. Även utbildning, handledning och fortbildning kan erbjudas.
Address
Karlsgatan 4
Phone
+46764969051
Email
patrik.myren@krehab.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 134 | 152 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −18 | 117 | 139 | −13 | −16 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −18 | 117 | 139 | −13 | −16 |
| Net financials | −2 952 | −45 | −827 | 816 | 693 |
| Profit before tax | 1 308 | 72 | −78 | 1 173 | 677 |
| Tax | −0 | −0 | −146 | −68 | — |
| Net profit | 1 308 | 72 | −224 | 1 105 | 677 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 9 059 | 9 458 | 8 389 | 10 696 | 10 055 |
| Equity | 6 725 | 6 798 | 6 574 | 7 679 | 8 356 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 354 | 1 681 | 1 445 | 3 017 | 1 699 |
| Total debt | 1 354 | 1 681 | 1 445 | 3 017 | 1 699 |
EBITDA margin
-1568800.0%
This company
15.8%
Market median
-9929214% vs market
20202024
Equity ratio
83.1%
This company
38.2%
Market median
+118% vs market
20202024
Return on equity
8.1%
This company
18.4%
Market median
-56% vs market
20202024
Net profit margin
67717000.0%
This company
8.1%
Market median
+836012246% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Neurova AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Patrik Jan Myrén | Board of Directors | 0 companies |
| Kjell Roger Gunnar Andersson | Deputy Board Member | 0 companies |